• CSS Log In
  • Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long Non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • CLIA/CAP Whole Exome Sequencing
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Webinars
  • About
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial Denovo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Webinars
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • お問い合わせは こちら
    皆様の研究の ニーズに関して お気軽にご相談ください
    Clinical Panels

    NovoFocus™ CR

    Individuals who are carriers of hereditary pathogenic variants exhibit a higher risk (usually ≥50%) of developing cancers during their lifetime. These cancer-related variants are the predisposition to cancer. Therefore, early detection gives you opportunity to maximize health outcomes for your high-risk patients group with patient-tailored screening programs, preventive measures and proactive treatment.

    Parameters

    NovoFocus™ CR
    Cancer Type
    Multiple Cancers
    Sample Type
    ≥ 5ml Blood
    Turnaround Time
    15 Calendar Days
    Novogene Quality Assurance
    Comprehensive Gene Coverage for Herediatary Cancer Screening

    Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes which are recommended by international guidelines.

    Advanced Technology

    Using NGS platform and unique proprietary technology, assess the SNP, InDel, and large fragment deletions at once.

    Authoritative Database

    Integrated internationally recognized databases to interpret data and generate report.

    Competitive Price

    With top tier sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all our services.

    Who Benefits from NovoFocus™ CR ?
  • Individuals with a positive family history (several generations) of same or different cancers.
  • Anyone who would like to find out more about their risk of developing cancer.
  • NovoFocus™ CR Workflow

    Gene listNovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.

    What Does NovoFocus™ CR Detect?

    Associated Genes Across 8 Important Hereditary Cancer Types
    Genes
    Breast
    Ovarian
    Colorectal
    Uterine
    Renal
    Pancreatic
    Gastric
    Prostate
    Others
    APC
    ATM
    AXIN2
    BARD1
    BRCA1
    BRCA2
    BRIP1
    BUB1
    BUB1B
    BUB3
    CDH1
    CDKN2A
    CHEK2
    ELAC
    EPCAM
    FH
    FLCN
    HNF1A
    HOXB13
    MET
    MLH1
    MLH3
    MSH2
    MSH6
    MUTYH
    NBN
    PALB2
    PMS1
    PMS2
    PRSS1
    PTEN
    RAD51C
    RAD51D
    RNASEL
    SDHA/SDHB
    SDHC/SDHD
    SMAD4
    STK11
    TP53
    VHL

    Data Interpretations

    (*OMIM Database and NCCN Guidelines)

    Positive Results Uncertain Variants Negative Results
    Pathogenic/Likely pathogenic Medical Management Based on Recommendations for the Specific Variants
    Uncertain Significance Variant Surveillance and Medical Management Based on Personal/Family Cancer History
    Likely benign/Benign Recommendations based on general population cancer risk screening